{
  "pmid": "40888434",
  "title": "Amlitelimab, an anti-OX40 ligand antibody, for atopic dermatitis: a plain language summary of STREAM-AD clinical study.",
  "abstract": "",
  "pub_date": "2025-09-01",
  "publication_types": [
    "Journal Article"
  ],
  "affiliations": [
    "aDepartment of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, Germany.",
    "bBlauvelt Consulting, LLC, Annapolis, MD, USA.",
    "cAlliance Clinical Trials and Probity Medical Research, Waterloo, Ontario, Canada; and Division of Dermatology, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.",
    "dDepartment of Dermatology, University of Rzeszow, Rzeszow, Poland.",
    "eDepartment of Dermatology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.",
    "fDivision of Allergy and Immunology, Department of Dermatology, Venereology and Allergy, Charité Universitätsmedizin Berlin, Berlin, Germany.",
    "gProbity Medical Research, and University of Toronto, Markham, Ontario, Canada.",
    "hDepartment of Dermatology, Osaka Habikino Medical Center, Habikino, Japan.",
    "iDepartment of Dermatology, St Vincent's Hospital Melbourne, Fitzroy, Australia; Skin Health Institute, Carlton, Australia; The University of Melbourne, Parkville, Victoria, Australia.",
    "jFormerly Sanofi, Bridgewater, NJ, USA.",
    "kSanofi, Paris, France.",
    "kSanofi, Paris, France.",
    "kSanofi, Paris, France.",
    "lSanofi, Cambridge, MA, USA.",
    "lSanofi, Cambridge, MA, USA.",
    "mSanofi, Montpellier, France.",
    "nSanofi, Cambridge, UK.",
    "oSanofi, Basel, Switzerland.",
    "lSanofi, Cambridge, MA, USA.",
    "kSanofi, Paris, France."
  ],
  "url": "https://pubmed.ncbi.nlm.nih.gov/40888434/",
  "snapshot_id": "2026-02-12T15-12-29Z",
  "ingested_at": "2026-02-12T15:12:33.030557+00:00"
}